Add to ORKGTiotropium Respimat increases mortality risk. First do no harm. Tiotropium Respimat should not be prescribed in COP
No abstract available. Article truncated at 150 words. Tiotropium, a long-acting inhaled anticholing...
The cardiovascular safety of tiotropium Respimat formulation in the routine clinical practice is sti...
Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg once da...
Tiotropium, a long-acting anticholinergic, is delivered via HandiHaler or via Respimat. Randomised c...
disease (COPD) [1–4]. While a decrease in mortality was observed for tiotropium HandiHaler ® versus ...
Background Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy simila...
makes a speculative recommendation that tiotropium Respimat should not be pre-scribed in the treatme...
Background: Tiotropium has been associated with an increased risk of mortality and/or cardiovascular...
INTRODUCTION: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (C...
differential effects of tiotropium on mortality in COPD’ We thank Dr Lipworth1 for his response to o...
Inhaled therapies reduce risk of chronic obstructive pulmonary disease (COPD) exacerbations, but the...
The majority of deaths in COPD are from cardiovascular causes. Several large randomized controlled t...
IMPORTANCE OF THE FIELD: Anticholinergic agents are of noteworthy value in the treatment of chronic ...
The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an o...
David MG Halpin,1 Ronald Dahl,2 Christoph Hallmann,3 Achim Mueller,3 Donald Tashkin4 1NHS SW, Royal ...
No abstract available. Article truncated at 150 words. Tiotropium, a long-acting inhaled anticholing...
The cardiovascular safety of tiotropium Respimat formulation in the routine clinical practice is sti...
Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg once da...
Tiotropium, a long-acting anticholinergic, is delivered via HandiHaler or via Respimat. Randomised c...
disease (COPD) [1–4]. While a decrease in mortality was observed for tiotropium HandiHaler ® versus ...
Background Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy simila...
makes a speculative recommendation that tiotropium Respimat should not be pre-scribed in the treatme...
Background: Tiotropium has been associated with an increased risk of mortality and/or cardiovascular...
INTRODUCTION: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (C...
differential effects of tiotropium on mortality in COPD’ We thank Dr Lipworth1 for his response to o...
Inhaled therapies reduce risk of chronic obstructive pulmonary disease (COPD) exacerbations, but the...
The majority of deaths in COPD are from cardiovascular causes. Several large randomized controlled t...
IMPORTANCE OF THE FIELD: Anticholinergic agents are of noteworthy value in the treatment of chronic ...
The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an o...
David MG Halpin,1 Ronald Dahl,2 Christoph Hallmann,3 Achim Mueller,3 Donald Tashkin4 1NHS SW, Royal ...
No abstract available. Article truncated at 150 words. Tiotropium, a long-acting inhaled anticholing...
The cardiovascular safety of tiotropium Respimat formulation in the routine clinical practice is sti...
Tiotropium is now delivered via two different inhaler devices: the original Handihaler 18 μg once da...